Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureMatthew A. Cavender, Ania M. Jastreboff, Alice Y.Y. Cheng, Melanie J. Davies, Lucienne Donaldson, Lars-Ole Gerlach, Silas Hinsch Gylvin, Jacob Bonde Jacobsen, Nikolaus Marx, Cynthia Karenina Osorto Contreras, Carel W. Le Roux, A. Michael Lincoff
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
A tale of coronary artery disease and myocardial infarction
10.1056/nejmra1112570 · 2012
Global Burden of Cardiovascular Diseases Risks 2023 Collaborators. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023
2025
Obesity in adults
10.1016/s0140-6736(24)01210-8 · 2024
Effect of weight loss on blood pressure changes in overweight patients: a systematic review and meta-analysis
10.1111/jch.14661 · 2023
Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants
10.1016/s0140-6736(13)61836-x · 2014
Cardiovascular-liver-metabolic health: Recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach
10.1161/circulationaha.124.070535 · 2025
Association of initial and longitudinal changes in C-reactive protein with the risk of cardiovascular disease, cancer, and mortality
10.1016/j.mayocp.2022.10.013 · 2023
Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement: A Report of the American College of Cardiology
2025
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
Nutrient-Stimulating Hormone-Based Therapies for Obesity
10.1016/j.ecl.2024.10.006 · 2025
A structural basis for amylin receptor phenotype
10.1126/science.abm9609 · 2022
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
10.1016/s0140-6736(21)01751-7 · 2021
Amylin - Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity
10.1016/j.molmet.2017.11.009 · 2018
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial
10.1016/s0140-6736(21)00845-x · 2021
Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial
10.1007/s00125-017-4289-0 · 2017
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
10.1056/nejmoa1607141 · 2016
Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes
10.1056/nejmoa2501006 · 2025
Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials
2025
Semaglutide and cardiovascular outcomes in obesity without diabetes
10.1056/nejmoa2307563 · 2023
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
10.1016/s0140-6736(25)00509-4 · 2025
Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
10.1016/s0140-6736(23)01163-7 · 2023
Coadministered cagrilintide and semaglutide in adults with overweight or obesity
10.1056/nejmoa2502081 · 2025
Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes
10.1056/nejmoa2502082 · 2025
CagriSema reduces blood pressure in adults with overweight or obesity: REDEFINE 1
10.1161/hypertensionaha.125.26055 · 2026
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
10.1016/s2213-8587(26)00125-7 · 2026
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
10.1056/nejmoa2215024 · 2023
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
10.1056/nejmoa1615664 · 2017
Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial
10.1002/oby.24332 · 2025
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
10.1056/nejmoa2514428 · 2026
2017 cardiovascular and stroke endpoint definitions for clinical trials
10.1161/circulationaha.117.033502 · 2018
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests
10.1002/bimj.201000239 · 2011
Lipid-lowering treatment patterns and risk of subsequent cardiovascular outcomes in patients with recent coronary revascularization
2026
Oral semaglutide and heart failure outcomes in persons with type 2 diabetes: a secondary analysis of the SOUL randomized clinical trial
10.1001/jamainternmed.2025.7774 · 2026
Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials
10.1016/j.metabol.2025.156463 · 2026
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
10.1056/nejmoa2403664 · 2024
Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists
10.1001/jamanetworkopen.2025.53323 · 2026
Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial
2024
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial
10.1016/s0140-6736(25)01375-3 · 2025
Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT
10.2337/dc24-0764 · 2024
Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes
10.1056/nejmoa1901118 · doi-reference
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
10.1016/s0140-6736(25)01776-3 · doi-reference
Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes
10.1056/nejmoa2505928 · doi-reference
Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes
10.1186/s12933-022-01601-w · doi-reference
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
10.1186/s12933-022-01585-7 · doi-reference
Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis
10.1056/nejmoa2413258 · doi-reference
Effect of Semaglutide on Atrial Arrhythmias Recurrence Following Ablation for Atrial Fibrillation: A Prospective Study
10.1161/circep.125.014069 · doi-reference
Semaglutide in patients with obesity-related heart failure and type 2 diabetes
10.1056/nejmoa2313917 · doi-reference
Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
10.1161/circulationaha.117.028136 · doi-reference